Sehitkamil

This research aims to evaluate the effects of Pilates ball exercises and manual sacral massage during labor on labor pain, labor duration, and childbirth satisfaction. The study is a randomized controlled trial that includes 105 pregnant women divided equally into three groups Pilates ball, sacral massage, and a control group with no intervention. The investigation is motivated by the need for low-cost, non-invasive methods to help manage labor pain and improve childbirth experience, especially methods that can be easily applied in maternity clinics. During the active phase of labor, women in the sacral massage group will receive effleurage and vibration techniques on the sacral region once every hour for up to 10 minutes. Those in the Pilates ball group will perform pelvic oscillation movements on a ball, such as hip rotations and gentle bouncing, once an hour during labor. The control group will receive standard care without additional interventions. The study will be conducted between December 2024 and May 2025 at two public hospitals. Participants will be assessed using various tools, including a Visual Analog Scale for pain intensity, Partograph to monitor labor duration, and a Labor Satisfaction Scale to measure maternal satisfaction. Data collection involves forms to record personal information, labor progress, and intervention details. Researchers will analyze the data to determine how these non-pharmacological methods affect labor outcomes. The study period includes labor monitoring and post-intervention satisfaction evaluation.

Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.